Biomedical Research Foundation Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2012
NCT01726088
First Marketed Drug
2015
sodium fluoride (18F)
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

BIOMEDCL RES FDN

Active Ingredients

Marketed Drugs (3)

ammonia n-13 (2015)

fludeoxyglucose f-18 (2015)

sodium fluoride (18F) (2015)

Drugs in Phase 3 Trials (1)

modafinil (provigil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stress Disorders, Post-Traumatic (Phase 3)

Stress Disorders, Traumatic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1